Related Experiment Video
Updated: Jul 16, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Cirrhotic cardiomyopathy
A Milani1, R Zaccaria, G Bombardieri
1Department of Internal Medicine, Catholic University of Rome, Italy. amilani@freemail.it
Insights
Cirrhotic cardiomyopathy, a heart condition in liver cirrhosis patients, involves impaired heart function masked by vasodilation. Treatments that increase blood volume can unmask this condition, leading to heart failure.
Area of Science:
- Cardiology
- Hepatology
- Internal Medicine
Background:
- Decompensated liver cirrhosis presents with peripheral vasodilation and hyperdynamic circulation.
- This sustained cardiac workload can lead to heart abnormalities, termed "cirrhotic cardiomyopathy."
- Cirrhotic cardiomyopathy is characterized by increased cardiac output, impaired contractility, and altered response to stimuli.
Purpose of the Study:
- To describe the clinical entity of cirrhotic cardiomyopathy.
- To outline the cardiac abnormalities associated with liver cirrhosis.
- To identify conditions that may unmask latent cirrhotic cardiomyopathy.
Main Methods:
- Literature review and synthesis of existing research on cirrhotic cardiomyopathy.
- Analysis of clinical characteristics and hemodynamic changes in cirrhotic patients.
- Review of treatment interventions that impact cardiac function in cirrhosis.
Main Results:
- Cirrhotic cardiomyopathy often presents subclinically due to reduced afterload from vasodilation.
- Key features include increased cardiac output, defective myocardial contractility, and impaired beta-adrenergic function.
- Interventions like shunts or liver transplantation can increase preload, unmasking heart failure.
Conclusions:
- Cirrhotic cardiomyopathy is a distinct clinical entity in decompensated liver cirrhosis.
- The condition is often masked but can be revealed by interventions that alter hemodynamics.
- Recognizing and managing cirrhotic cardiomyopathy is crucial for cirrhotic patients undergoing certain treatments.
Abstract:
Decompensated liver cirrhosis is characterized by a peripheral vasodilation with a low-resistance hyperdynamic circulation. The sustained increase of cardiac work load associated with such a condition may result in an inconstant and often subclinical series of heart abnormalities, constituting a new clinical entity known as "cirrhotic cardiomyopathy". Cirrhotic cardiomyopathy is variably associated with baseline increase in cardiac output, defective myocardial contractility and lowered systo-diastolic response to inotropic and chronotropic stimuli, down-regulated beta-adrenergic function, slight histo-morphological changes, and impaired electric "recovery" ability of ventricular myocardium. Cirrhotic cardiomyopathy is usually clinically latent or mild, likely because the peripheral vasodilation significantly reduces the left ventricle after-load, thus actually "auto-treating" the patient and masking any severe manifestation of heart failure. In cirrhotic patients, the presence of cirrhotic cardiomyopathy may become unmasked and clinically evident by certain treatment interventions that increase the effective blood volume and cardiac pre-load, including surgical or transjugular intrahepatic porto-systemic shunts, peritoneo-venous shunts (LeVeen) and orthotopic liver transplantation. Under these circumstances, an often transient overt congestive heart failure may develop, with increased cardiac output as well as right atrial, pulmonary artery and capillary wedge pressures.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cirrhosis I: Introduction

